Gulf International Bank UK Ltd Continues to Hold Position in Amgen Inc. (AMGN)

Gulf International Bank UK Ltd held its stake in Amgen Inc. (NASDAQ:AMGN) during the second quarter, Holdings Channel reports. The institutional investor owned 231,871 shares of the medical research company’s stock at the end of the second quarter. Gulf International Bank UK Ltd’s holdings in Amgen were worth $39,935,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in AMGN. Chevy Chase Trust Holdings Inc. increased its stake in Amgen by 2.0% in the first quarter. Chevy Chase Trust Holdings Inc. now owns 674,068 shares of the medical research company’s stock worth $110,595,000 after buying an additional 13,063 shares during the last quarter. McQueen Ball & Associates Inc. increased its stake in Amgen by 5.6% in the first quarter. McQueen Ball & Associates Inc. now owns 11,067 shares of the medical research company’s stock worth $1,816,000 after buying an additional 583 shares during the last quarter. Private Asset Management Inc. increased its stake in Amgen by 117.8% in the first quarter. Private Asset Management Inc. now owns 3,591 shares of the medical research company’s stock worth $589,000 after buying an additional 1,942 shares during the last quarter. Franklin Street Advisors Inc. NC increased its stake in Amgen by 12.5% in the first quarter. Franklin Street Advisors Inc. NC now owns 2,742 shares of the medical research company’s stock worth $450,000 after buying an additional 305 shares during the last quarter. Finally, Integrated Investment Consultants LLC increased its stake in Amgen by 5.5% in the first quarter. Integrated Investment Consultants LLC now owns 6,921 shares of the medical research company’s stock worth $1,136,000 after buying an additional 360 shares during the last quarter. Institutional investors own 79.53% of the company’s stock.

Shares of Amgen Inc. (NASDAQ AMGN) traded up 0.12% during mid-day trading on Friday, hitting $169.31. 725,750 shares of the company traded hands. Amgen Inc. has a 1-year low of $133.64 and a 1-year high of $184.21. The firm’s 50 day moving average price is $174.60 and its 200-day moving average price is $167.37. The stock has a market capitalization of $123.54 billion, a PE ratio of 15.42 and a beta of 1.35.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.11 by $0.16. The business had revenue of $5.81 billion for the quarter, compared to analyst estimates of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The company’s revenue was up 2.1% on a year-over-year basis. During the same quarter last year, the firm earned $2.84 EPS. On average, equities research analysts forecast that Amgen Inc. will post $12.57 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Thursday, August 17th will be paid a dividend of $1.15 per share. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.72%. The ex-dividend date is Tuesday, August 15th. Amgen’s payout ratio is 41.93%.

TRADEMARK VIOLATION WARNING: “Gulf International Bank UK Ltd Continues to Hold Position in Amgen Inc. (AMGN)” was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.com-unik.info/2017/08/11/gulf-international-bank-uk-ltd-continues-to-hold-position-in-amgen-inc-amgn.html.

A number of equities research analysts have recently weighed in on the stock. BMO Capital Markets downgraded shares of Amgen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, July 26th. Oppenheimer Holdings, Inc. restated an “outperform” rating and set a $203.00 price objective (up from $189.00) on shares of Amgen in a research report on Wednesday, July 26th. Deutsche Bank AG restated a “hold” rating and set a $174.00 price objective (up from $172.00) on shares of Amgen in a research report on Wednesday, July 26th. Cann restated a “buy” rating and set a $203.00 price objective (up from $189.00) on shares of Amgen in a research report on Wednesday, July 26th. Finally, Cowen and Company restated an “outperform” rating and set a $209.00 price objective on shares of Amgen in a research report on Saturday, July 22nd. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company. Amgen has an average rating of “Buy” and a consensus price target of $186.64.

In other news, SVP Cynthia M. Patton sold 2,922 shares of Amgen stock in a transaction dated Wednesday, May 24th. The shares were sold at an average price of $154.40, for a total transaction of $451,156.80. Following the sale, the senior vice president now owns 24,214 shares of the company’s stock, valued at approximately $3,738,641.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.20% of the company’s stock.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

What are top analysts saying about Amgen Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Amgen Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit